Cerecor

$3.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.22 (-6.38%) Today
$0.00 (0.00%) As of 9:00 PM UTC after-hours

Why Robinhood?

You can buy or sell Cerecor and other stocks, options, and ETFs commission-free!

About CERC

Cerecor, Inc. engages in the development and commercialization of treatments for rare pediatric and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD. The listed name for CERC is Cerecor Inc. Common Stock.

CEO
Michael F. Cola
Employees
18
Headquarters
Rockville, Maryland
Founded
2011
Market Cap
259.44M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.09M
High Today
$3.50
Low Today
$3.10
Open Price
$3.39
Volume
919.81K
52 Week High
$4.50
52 Week Low
$1.52

CERC News

BenzingaMar 2

Cerecor Shares Are Trading Higher On Positive CERC-002 Efficacy Data In COVID-19 Study

Cerecor Inc (NASDAQ: CERC) shares gained premarket on the heels of final efficacy data, including 60-day mortality from the Phase 2 trial evaluating CERC-002 in

CERC Earnings

-$0.36
-$0.22
-$0.07
$0.07
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 10, After Hours

You May Also Like

GTEC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure